Research and consensus on activity evaluation technologies for recombinant enzyme drugs and key enzyme-based raw and auxiliary materials*

LI Jing

Chinese Journal of Pharmaceutical Analysis ›› 2026, Vol. 46 ›› Issue (4) : 572-581.

Chinese Journal of Pharmaceutical Analysis ›› 2026, Vol. 46 ›› Issue (4) : 572-581. DOI: 10.16155/j.0254-1793.2026-0124
Special Column on the R&D Status and Quality Control of Innovative Therapeutic Biologics

Research and consensus on activity evaluation technologies for recombinant enzyme drugs and key enzyme-based raw and auxiliary materials*

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2026, 46(4): 572-581 https://doi.org/10.16155/j.0254-1793.2026-0124

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-4
Copyright © Chinese Journal of Pharmaceutical Analysis, All Rights Reserved.
E-mail：ywfx@nifdc.org.cn
Powered by Beijing Magtech Co. Ltd.

/

〈 〉